Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

The prognostic role and association of 18F-FDG PET CT and HER2 expression in gastric cancer

Date

08 Oct 2016

Session

Poster Display

Presenters

Ji Soo Park

Citation

Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371

Authors

J.S. Park1, N. Lee2, J.H. Kim3, H.S. Park3, S.J. Heo3, S.H. Beom3, H.S. Kim3, S.Y. Rha3, H.C. Chung3, M. Yun2, A. Cho2, M. Jung3

Author affiliations

  • 1 Cancer Prevention Center, Yonsei Cancer Center, 03722 - Seoul/KR
  • 2 Department Of Nuclear Medicine, Yonsei Cancer Center, Seoul/KR
  • 3 Division Of Medical Oncology, Yonsei Cancer Center, Seoul/KR
More

Resources

Background

Human epidermal receptor 2 (HER2) status predicts therapy response with antibody targeted to HER2 in gastric cancer. The objective of this study was to examine the clinical value and relationship of pretreatment fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography (18F-FDG PET/CT) and HER2 status in gastric cancer.

Methods

Retrospective review of 141 gastric cancer patients at our institution between January 2005 and December 2014 who had baseline 18F-FDG-PET/CT before chemotherapy. SUVmax of the primary lesion was recorded, and whole body metastatic burden was calculated using PET metabolic parameters (SUVmax, SUVmean, MTV, TLG) on all metabolically active metastatic lesions (SUV threshold ≥2.5 or 40% isocontour for ≤2.5).

Results

Gastric cancers of HER2 positivity had higher FDG uptake compared to HER2 negative of diffuse type pathology (SUVmax of the primary lesion, 9.9 vs. 5.9, p 

Conclusions

HER2 positive gastric cancer had higher FDG uptake in the primary lesion compared to HER2 negative cancers, and had higher metabolically active metastatic burden. In addition, whole body TLG and MTV may be more useful than SUVmean and SUVmax for predicting survival in gastric cancer.

Clinical trial identification

Legal entity responsible for the study

None

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings